New Amgen data highlights promise in gastric cancer
The top-line Phase III findings illustrate potential of the monoclonal antibody plus chemotherapy as a first-line gastric cancer treatment.
List view / Grid view
The top-line Phase III findings illustrate potential of the monoclonal antibody plus chemotherapy as a first-line gastric cancer treatment.
While the pharmaceutical market is expected to witness strong pricing competition, there is also significant opportunity for biotech companies, research says.
The study represents the first time the injectable gene therapy has been evaluated in teenagers and adults.
In this article, Stacey Ramsey, Senior Manager – Microbial Applications Lab, Charles River Laboratories, discusses the modernisation of rapid microbiological methods (RMMs) and the potential of ATP-bioluminescence when testing cell-based products.
The new acquisition, worth up to $2.1 billion, gives AbbVie rights to a potential first-in-class drug for B cell-mediated autoimmune diseases.
Cell therapy expert Lindsay Davies, PhD, FHEA, discusses the key considerations for moving the needle to broader adoption of CGTs in Europe.
The deal between Gilead Sciences and Kymera Therapeutics could lead to development of safer and more effective cancer treatments.
27 June 2025 | By Thermo Fisher Scientific
This webinar will explore how lipid formulations in softgels can enhance drug absorption and bioavailability.
The investigational dual-targeting treatment provided strong and durable delivery to tumours, allowing for a high dose of targeted radiation, early results show.
EPR Issue 2 includes articles on the impact of tariffs on the pharmaceutical supply chain, advances in bioprocessing, manufacturing and more.
The genetically edited allogeneic product could serve as an immune-modulatory therapy for severe autoimmune diseases, data suggests.
The new UK strategy represents a milestone for enhancing international competitiveness and puts into motion the upcoming Life Sciences Sector Plan.
The cell and gene therapy (CGT) sector must maintain its scientific rigor despite recent changes to US policy and market conditions, says key industry body.
The proposed synthesis system offers potential for scalable production of β-blockers, new research suggests.
The committee’s final draft guidance cited high-cost as a key reason for its negative opinion of the Alzheimer’s drugs, developed by Biogen and Eisai.